Aptahem AB (publ) announce today that the collaboration with the Cardiovascular Research Centre (CVRC) at Örebro University to map the details behind Apta-1’s effects with the support from the Knowledge Foundation’s Prospect Call now has generated results that clarify...
Read MoreBioStock published an article on 26 May 2021 about Aptahem, which can be read in full below. The most anticipated milestone for sepsis company Aptahem is initiating first-in-human trials with candidate Apta-1, which is planned for next year. BioStock...
Read MoreBioStock published an article on 5 May 2021 about Aptahem, which can be read in full below. Biotechnology company Aptahem, which is developing the preclinical drug candidate Apta-1 for the treatment of sepsis, recently announced that it has suspended...
Read MoreBioStock published an article on 24 March 2021 about Aptahem, which can be read in full below. Aptahem is developing the drug candidate Apta-1 as an emergency treatment for sepsis, a life-threatening condition that is relatively unknown to the...
Read MoreBioStock published an article on 10 March 2021 about Aptahem, which can be read in full below. Aptahem announced yesterday that the company has entered into a non binding Term Sheet (NBTS) with a European pharmaceutical company. The NBTS...
Read MoreAptahem AB (publ) announce today that the company has signed an NBTS (non binding Term Sheet) with a mid-sized pharmaceutical company with head quarters in Europe. The NBTS relates to license terms for exclusive development, manufacturing and distribution of...
Read MoreAptahem AB (publ) announce today that the company has signed an agreement with their collaboration partner LGC Group to initiate the GMP (Good Manufacturing Practice) manufacturing of Apta-1. With this agreement, Aptahem ensures that the previously communicated schedule is...
Read MoreAptahem AB (publ) announce today that the company has received patent approval in India for patent family 1, with patent application number 6250/DELNP/2010. The patent, with the patent number 353024, covers the protection of the company’s aptamer structures. The...
Read MoreBioStock published an article on 22 December 2020 about Aptahem, which can be read in full below. Aptahem, which is developing an emergency medicine for the treatment of sepsis, carried out an oversubscribed rights issue in October. During the...
Read MoreBioStock published an article on 8 December 2020 about Aptahem, which can be read in full below. Aptahem, whose primary drug candidate Apta-1 is being developed as an emergency treatment targeting sepsis, has been able to make several key...
Read More